Abstract: A video coding device may identify a network abstraction layer (NAL) unit. The video coding device may determine whether the NAL unit includes an active parameter set for a current layer. When the NAL unit includes the active parameter set for the current layer, the video coding device may set an NAL unit header layer identifier associated with the NAL unit to at least one of: zero, a value indicative of the current layer, or a value indicative of a reference layer of the current layer. The NAL unit may be a picture parameter set (PPS) NAL unit. The NAL unit may be a sequence parameter set (SPS) NAL unit.

Abstract: Systems, methods, and instrumentalities are provided to implement weighted prediction (WP) signaling, A decoding device may receive a plurality of first list WP parameters, and a. weights present flag. The weights present flag may indicate whether a plurality of second list WP parameters are signaled. The decoding device may receive the second list WP parameters when the weights present flag indicates that the second list WP parameters are signaled. The plurality of second list WP parameters may be derived when the weights present flag indicates that the second list WP parameters are not signaled. The decoding device may receive a delta parameter present, flag, which may indicate whether a plurality of delta WP parameters are signaled. The decoding device may receive the delta WP parameters, when the delta parameter present flag indicates that the plurality of the delta WP parameters are signaled.

Abstract: Embodiments include processes, systems, and devices for reshaping virtual baseband signals for transmission on non-contiguous and variable portions of a physical baseband, such as a white space frequency band. In the transmission path, a spectrum virtualization layer maps a plurality of transmission components associated with a transmission symbol produced by a physical layer protocol to sub-carriers of the allocated physical frequency band. The spectrum virtualization layer then outputs a physical transmission symbol composed of time-domain samples derived from the mapped frequency components and a cyclic prefix. In the receive path, a time-domain symbol received on the physical baseband is reshaped and equalized by the virtual spectrum layer in order to recompose a time-domain samples of a transmission stream in the virtual baseband.

Abstract: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit ?-lactamases of class A, class C or class D and potentiate ?-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a ?-lactam antibiotic at a fixed concentration have an MIC of 8 ?g/mL or less against one or more isogenic ?-lactamase expressing bacterial strains.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit ?-lactamases of class A, class C or class D and potentiate ?-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a ?-lactam antibiotic at a fixed concentration have an MIC of 8 ?g/mL or less against one or more isogenic ?-lactamase expressing bacterial strains.

Abstract: Embodiments include processes, systems, and devices for reshaping virtual baseband signals for transmission on non-contiguous and variable portions of a physical baseband, such as a white space frequency band. In the transmission path, a spectrum virtualization layer maps a plurality of transmission components associated with a transmission symbol produced by a physical layer protocol to sub-carriers of the allocated physical frequency band. The spectrum virtualization layer then outputs a physical transmission symbol composed of time-domain samples derived from the mapped frequency components and a cyclic prefix. In the receive path, a time-domain symbol received on the physical baseband is reshaped and equalized by the virtual spectrum layer in order to recompose a time-domain samples of a transmission stream in the virtual baseband.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., Pseudomonas aeruginosa) and Gram-positive (e.g., methicillin-resistant Staphylococcus aureus) bacteria. Methods of manufacturing the compound of formula (I), and uses of the compound in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: An optical connector includes an insulative housing, an optical module movably retained on the insulative housing, and a spring being assembled between the insulative housing and the optical module along a front to back direction. The optical module has a hemispheric projection at a rear side thereof. The spring has a first end positioned on the insulative housing and a second end ringing on the projection and resisting against a hemispheric surface of the projection. The second end moves on the hemispheric surface of the projection when the spring is compressed to move upwardly or laterally.

Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Abstract: Embodiments include processes, systems, and devices that allow a white space base station to request available frequency ranges for white space transmission in a local area. A white space finder service models a primary user device's transmission signal propagation area using terrain data associated with the local area of the primary user device. The white space finder service also determines, based on the location of the white space base station and the modeled propagation area, one or more locally available, non-interfering frequency ranges and provides them to the white space base station. The white space base station compares the provided frequency ranges to policies and selects one or more of the available frequencies that accommodate the policies. The white space base station also maps the transmission frequency ranges to virtual frequency ranges for transmission by a software-defined radio employing spectrum virtualization.